<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="have beneficial effects in COVID-19 therapy [111, 134]. Remdesivir and" exact="chloroquine" post="have been reported to inhibit SARS-CoV-2 in vitro [35]"/>
 <result pre="proved enough efficacy in clinical trials. In the case of" exact="chloroquine" post="and hydroxychloroquine, although initially was thought to be useful"/>
 <result pre="is insufficient evidence to support the effectiveness or safety of" exact="hydroxychloroquine" post="or chloroquine for the treatment of COVID-19 in hospitalized"/>
 <result pre="evidence to support the effectiveness or safety of hydroxychloroquine or" exact="chloroquine" post="for the treatment of COVID-19 in hospitalized patients as"/>
 <result pre="but its clinical utility remains to be confirmed [142–144]. Remdesivir," exact="chloroquine" post="and hydroxychloroquine though being used in COVID-19 patients under"/>
 <result pre="clinical utility remains to be confirmed [142–144]. Remdesivir, chloroquine and" exact="hydroxychloroquine" post="though being used in COVID-19 patients under the common"/>
 <result pre="or in combination with IFN-α in COVID-19 patients [156]. Tocilizumab," exact="ivermectin" post="does not have RCTs yet, although they have preclinical"/>
 <result pre="[167, 168]. During the SARS outbreak, HIV protease inhibitors like" exact="lopinavir" post="and ritonavir had positive efficacy [169]. In vitro and"/>
 <result pre="During the SARS outbreak, HIV protease inhibitors like lopinavir and" exact="ritonavir" post="had positive efficacy [169]. In vitro and in vivo"/>
 <result pre="better anti-viral efficacy as compared to the combined formula of" exact="lopinavir" post="and ritonavir in treating MERS-CoV infections [173]. Since the"/>
 <result pre="efficacy as compared to the combined formula of lopinavir and" exact="ritonavir" post="in treating MERS-CoV infections [173]. Since the novel coronavirus"/>
 <result pre="the People’s Republic of China has advocated the inclusion of" exact="chloroquine" post="phosphate for the cure of COVID-19 patients, in its"/>
 <result pre="as a model, three drugs, namely, cepharanthine (CEP), selamectin, and" exact="mefloquine" post="hydrochloride, were observed to possess anti-SARS-CoV-2 activity with complete"/>
 <result pre="cell cytopathic effects [177]. Chen et al. [18] have used" exact="oseltamivir" post="(75 mg), lopinavir (500 mg), ritonavir (500 mg) per"/>
 <result pre="[177]. Chen et al. [18] have used oseltamivir (75 mg)," exact="lopinavir" post="(500 mg), ritonavir (500 mg) per os twice daily"/>
 <result pre="al. [18] have used oseltamivir (75 mg), lopinavir (500 mg)," exact="ritonavir" post="(500 mg) per os twice daily followed by ganciclovir"/>
 <result pre="mg), ritonavir (500 mg) per os twice daily followed by" exact="ganciclovir" post="(0.25 g) intravenously for 3–14 days in COVID-19 infected"/>
 <result pre="[178]. Anti-viral proteases Anti-coronavirus protease activity was exhibited by the" exact="lopinavir" post="(LPV), and it is proposed as a treatment option"/>
 <result pre="ACE2 and AT1R (angiotensin receptor one blocker) molecules such as" exact="losartan" post="as inhibitors of the renin-angiotensin system (RAS) could be"/>
 <result pre="evaluated. Chen et al. [18] have used oseltamivir, lopinavir, ritonavir," exact="ganciclovir" post="in COVID-19 infected patients with excellent results; however, the"/>
 <result pre="controversial [165]. Other medications used are antibiotics (cephalosporins, quinolones, carbapenems," exact="tigecycline" post="against methicillin-resistant Staphylococcus aureus, linezolid, moxifloxacin or levofloxacin, azithromycin"/>
 <result pre="antibiotics (cephalosporins, quinolones, carbapenems, tigecycline against methicillin-resistant Staphylococcus aureus, linezolid," exact="moxifloxacin" post="or levofloxacin, azithromycin or amoxicillin, and antifungal drugs), corticosteroids"/>
 <result pre="carbapenems, tigecycline against methicillin-resistant Staphylococcus aureus, linezolid, moxifloxacin or levofloxacin," exact="azithromycin" post="or amoxicillin, and antifungal drugs), corticosteroids (prednisolone, dexamethasone), antipyretics"/>
 <result pre="135, 165, 189, 190]. Huang et al. [25] used antibiotics," exact="methylprednisolone" post="corticosteroid (40–120 mg per day), and oseltamivir (orally 75"/>
 <result pre="[25] used antibiotics, methylprednisolone corticosteroid (40–120 mg per day), and" exact="oseltamivir" post="(orally 75 mg twice daily) in COVID-19 patients along"/>
 <result pre="192]. National Health Commission of China recommended a combination of" exact="ribavirin" post="and interferon-α as a treatment regimen for COVID-19 in"/>
 <result pre="SARS-CoV in combination with antibiotics (moxifloxacin or levofloxacin, nemonoxacin, linezolid," exact="azithromycin" post="or amoxicillin), corticosteroids and oxygen therapy has been used"/>
 <result pre="promising candidates, including as mentioned combination therapies, including remdesivir, and" exact="ivermectin" post="[115]. Many newer drugs or candidates are being evaluated"/>
 <result pre="is disclosed, which comprises: administering a first effective amount of" exact="phenol" post="red and a second effective amount of an organic"/>
 <result pre="the race for patents. These include remdesivir of Gilead Sciences®," exact="hydroxychloroquine" post="of Sanofi® and Kaletra (Lopinavir+Ritonavir) of Abbvie®. They are"/>
 <result pre="242]. Chinese were first to evaluate the effectiveness of remdesivir," exact="chloroquine" post="and Kaletra in treating COVID-19 patients [25, 136]. However,"/>
 <result pre="and recent developmentsVet Q202040111231858882 101.collab: Health Commission ChinaExpert consensus on" exact="chloroquine" post="phosphate for the treatment of novel coronavirus pneumoniaChin J"/>
 <result pre="of COVID-19 pneumonia in a patient from Colombia after receiving" exact="chloroquine" post="and clarithromycinAnn Clin Microbiol Antimicrob20201911632331519 115.SandersJMMonogueMLJodlowskiTZCutrellJBPharmacologic Treatments for Coronavirus"/>
 <result pre="and pathogenesis of coronavirus disease (COVID-19) outbreakJ Autoimmun202010910243332113704 136.WangMCaoRZhangLYangXLiuJXuMShiZHuZZhongWXiaoGRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
 <result pre="Infection: A Randomized Clinical TrialJAMA Netw Open202034e20885732339248 139.LiuXChenHShangYZhuHChenGChenYLiuSZhouYHuangMHongZet al.Efficacy of" exact="chloroquine" post="versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label,"/>
 <result pre="Report. N Engl J Med. 2020. 146.GeversSKwaMSGWijnansEvan NieuwkoopCSafety considerations for" exact="chloroquine" post="and hydroxychloroquine in the treatment of COVID-19Clin Microbiol Infect20202691276127732422406"/>
 <result pre="Engl J Med. 2020. 146.GeversSKwaMSGWijnansEvan NieuwkoopCSafety considerations for chloroquine and" exact="hydroxychloroquine" post="in the treatment of COVID-19Clin Microbiol Infect20202691276127732422406 147.LiLWangXWangRHuYJiangSLuXAntiviral Agent"/>
 <result pre="Remdesivir for COVID-19: Data to Date. Cardiology. 2020. 149.LedfordHCoronavirus breakthrough:" exact="dexamethasone" post="is first drug shown to save livesNature2020582781346932546811 150.PatelSKSaikumarGRanaJDhamaJYatooMITiwariRRodríguez-MoralesAJDhamaKDexamethasone: A"/>
 <result pre="critically ill COVID-19 patients?Travel Med Infect Dis20203710184410184432791213 151.MahaseECovid-19: Demand for" exact="dexamethasone" post="surges as RECOVERY trial publishes preprintBMJ2020369m251232576548 152.Group RC, Horby"/>
 <result pre="a randomized controlled trialTrials2018191818129382391 171.FalzaranoDde WitERasmussenALFeldmannFOkumuraAScottDPBriningDBushmakerTMartellaroCBaselerLet al.Treatment with interferon-α2b and" exact="ribavirin" post="improves outcome in MERS-CoV-infected rhesus macaquesNat Med201319101313131724013700 172.WangZChenXLuYChenFZhangWClinical characteristics"/>
 <result pre="and interferon beta against MERS-CoVNat Commun202011122231924756 174.YaoT-TQianJ-DZhuW-YWangYWangG-QA systematic review of" exact="lopinavir" post="therapy for SARS coronavirus and MERS coronavirus-A possible reference"/>
 <result pre="the treatment of coronavirus COVID-19Int J Antimicrob Agents2020105944 197.CeccarelliGAlessandriFd’EttorreGBorrazzoCSpagnolelloOOlivaARubertoFMastroianniCMPuglieseFVendittiMet al.Is" exact="teicoplanin" post="a complementary treatment option for COVID-19? The question remainsInt"/>
 <result pre="the future. J Am Pharm Assoc. 2020. 254.DellapianaGNaqviMLeggettCTholemeierLBurwickRMPreferential use of" exact="dexamethasone" post="for fetal lung maturation in severe COVID-19Am J Obst"/>
</results>
